Abstract
The aim of this randomised study was to compare the effects of progestins and aromatase inactivators on bone remodelling markers and the components of insulin-like growth factor in patients with metastatic breast cancer. Within the framework of a large (769 patients), randomised double-blind clinical trial comparing exemestane (EXE) with megestrol acetate (MA), serum 17ß-estradiol (E2), estrone (E1), estrone sulphate (E1S), bone alkaline phosphatase (BAP), carboxy-terminal cross-linking telopeptide of type I collagen (ICTP) and the components of insulin-like growth factor (IGF) family (IGF-1, IGF-2 and IGFBP-3) were determined in 53 patients (24 randomised to EXE and 29 ramdomised to MA). After eight weeks of treatment, both ICTP and BAP increased (p2 and E1S was more pronounced in the EXE group (to, respectively, 11.2% and 9.9% of baseline values) than in the MA group (33.1% and 29.7%). IGF-1 increased (p
| Original language | English |
|---|---|
| Pages (from-to) | 3485-3491 |
| Number of pages | 7 |
| Journal | Anticancer Research |
| Volume | 23 |
| Issue number | 4 |
| Publication status | Published - Jul 2003 |
Fingerprint
Keywords
- Aromatase inhibitors
- Bone metabolism
- Cancer
- Exemestane
- Insulin-like growth factors
- Postmenopausal breast
- Tamoxifen
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Bone turnover markers and insulin-like growth factor components in metastatic breast cancer : Results from a randomised trial of exemestane vs megestrol acetate. / Martinetti, Antonia; Zilembo, Nicoletta; Ferrari, Leonardo; Massimini, Giorgio; Polli, Anna; La Torre, Ignazia; Giovanazzi, Riccardo; Pozzi, Paola; Bidoli, Paolo; De Candis, Daniela; Seregni, Ettore; Bombardieri, Emilio; Bajetta, Emilio.
In: Anticancer Research, Vol. 23, No. 4, 07.2003, p. 3485-3491.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bone turnover markers and insulin-like growth factor components in metastatic breast cancer
T2 - Results from a randomised trial of exemestane vs megestrol acetate
AU - Martinetti, Antonia
AU - Zilembo, Nicoletta
AU - Ferrari, Leonardo
AU - Massimini, Giorgio
AU - Polli, Anna
AU - La Torre, Ignazia
AU - Giovanazzi, Riccardo
AU - Pozzi, Paola
AU - Bidoli, Paolo
AU - De Candis, Daniela
AU - Seregni, Ettore
AU - Bombardieri, Emilio
AU - Bajetta, Emilio
PY - 2003/7
Y1 - 2003/7
N2 - The aim of this randomised study was to compare the effects of progestins and aromatase inactivators on bone remodelling markers and the components of insulin-like growth factor in patients with metastatic breast cancer. Within the framework of a large (769 patients), randomised double-blind clinical trial comparing exemestane (EXE) with megestrol acetate (MA), serum 17ß-estradiol (E2), estrone (E1), estrone sulphate (E1S), bone alkaline phosphatase (BAP), carboxy-terminal cross-linking telopeptide of type I collagen (ICTP) and the components of insulin-like growth factor (IGF) family (IGF-1, IGF-2 and IGFBP-3) were determined in 53 patients (24 randomised to EXE and 29 ramdomised to MA). After eight weeks of treatment, both ICTP and BAP increased (p2 and E1S was more pronounced in the EXE group (to, respectively, 11.2% and 9.9% of baseline values) than in the MA group (33.1% and 29.7%). IGF-1 increased (p
AB - The aim of this randomised study was to compare the effects of progestins and aromatase inactivators on bone remodelling markers and the components of insulin-like growth factor in patients with metastatic breast cancer. Within the framework of a large (769 patients), randomised double-blind clinical trial comparing exemestane (EXE) with megestrol acetate (MA), serum 17ß-estradiol (E2), estrone (E1), estrone sulphate (E1S), bone alkaline phosphatase (BAP), carboxy-terminal cross-linking telopeptide of type I collagen (ICTP) and the components of insulin-like growth factor (IGF) family (IGF-1, IGF-2 and IGFBP-3) were determined in 53 patients (24 randomised to EXE and 29 ramdomised to MA). After eight weeks of treatment, both ICTP and BAP increased (p2 and E1S was more pronounced in the EXE group (to, respectively, 11.2% and 9.9% of baseline values) than in the MA group (33.1% and 29.7%). IGF-1 increased (p
KW - Aromatase inhibitors
KW - Bone metabolism
KW - Cancer
KW - Exemestane
KW - Insulin-like growth factors
KW - Postmenopausal breast
KW - Tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=0042529168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042529168&partnerID=8YFLogxK
M3 - Article
C2 - 12926095
AN - SCOPUS:0042529168
VL - 23
SP - 3485
EP - 3491
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 4
ER -